CBIO FY 2022 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75,000-93.5% YoY

Gross Profit

$75,000100.0% margin

Operating Income

-$47M-63204.4% margin

Net Income

-$47M-62251.7% margin

EPS (Diluted)

$-0.89

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$47M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$52M

Total Liabilities

$9M

Stockholders' Equity

$43M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75,000	$1M	-93.5%
Gross Profit	$75,000	$1M	-93.5%
Operating Income	-$47M	-$63M	+25.3%
Net Income	-$47M	-$63M	+26.4%